Cosmo Pharmaceuticals NV (OTCPK:CMOPF)
$ 66.9252 0 (0%) Market Cap: 1.14 Bil Enterprise Value: 1.01 Bil PE Ratio: 15.34 PB Ratio: 2.13 GF Score: 84/100

Full Year 2022 Cosmo Pharmaceuticals NV Earnings Call Transcript

Mar 23, 2023 / 01:00PM GMT
Release Date Price: $61 (+0.58%)
Operator

Ladies and gentlemen, welcome to the -- Cosmo's Full Year 2022 Results and 2023 Outlook Conference Call and Webcast. I'm Ira, the Conference Call operator. (Operator Instructions) The conference is being recorded. (Operator Instructions) The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Mr. Mauro Ajani, Founder and Chairman. Please go ahead, sir.

Mauro Severino Ajani
Cosmo Pharmaceuticals N.V. - Founder & Executive Chairman

First of all, thank you, and good morning, everyone. Let me say that I am very happy and extremely excited today to be here. It was important for me to share with all of you my perspective on the great things that are happening here at Cosmo, and we have many great things that's happening. But today, I would like to focus on GI Genius.

I am sure that you read the different press release from us from Medtronic and also from NVIDIA. And I am sure you already realized how big and how important and strategic this news is. Let me say that we are at a pivotal moment with

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot